Gateway Investment Advisers LLC Acquires 131,364 Shares of Moderna, Inc. $MRNA

Key Points

• Gateway Investment Advisers boosted its Moderna stake by 1,445.1%, buying 131,364 shares to hold 140,454 shares valued at about $4.14 million.
• Moderna missed Q results on EPS (reported -$3.40 vs. -$3.02 expected) despite a revenue beat of $389 million (up ~260% year‑over‑year), and the company still shows negative margins with analysts forecasting a -$6.84 EPS for the year.
• Peer‑reviewed Phase 3 results for Moderna’s seasonal flu vaccine mRNA‑1010 were published in the NEJM showing it outperformed a standard shot (about ~27% better in older adults), supporting regulatory filings and potential approvals starting in 2026.

Gateway Investment Advisers LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1,445.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 140,454 shares of the company's stock after purchasing an additional 131,364 shares during the period. Gateway Investment Advisers LLC's holdings in Moderna were worth $4,142,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MUFG Securities EMEA plc bought a new position in Moderna during the second quarter worth about $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna during the fourth quarter worth about $31,000. Cromwell Holdings LLC grew its holdings in Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock worth $35,000 after purchasing an additional 341 shares during the period. Ameriflex Group Inc. grew its holdings in Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company's stock worth $32,000 after purchasing an additional 1,208 shares during the period. Finally, Kelleher Financial Advisors bought a new position in Moderna during the fourth quarter worth about $39,000. Institutional investors own 75.33% of the company's stock.

Moderna Trading Down 0.5%

Shares of NASDAQ:MRNA opened at $48.54 on Friday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55. The stock has a market cap of $19.26 billion, a PE ratio of -5.96 and a beta of 1.05. The business has a 50 day moving average of $51.70 and a 200-day moving average of $39.91. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same quarter in the prior year, the firm earned ($2.52) EPS. The company's revenue was up 260.2% on a year-over-year basis. As a group, equities research analysts forecast that Moderna, Inc. will post -6.84 earnings per share for the current year.

Insider Buying and Selling

In other news, President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56. Following the completion of the sale, the president directly owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director owned 12,066 shares of the company's stock, valued at approximately $562,637.58. The trade was a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.80% of the company's stock.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Peer‑reviewed Phase 3 results for Moderna’s investigational seasonal influenza vaccine mRNA‑1010 were published in the New England Journal of Medicine and show the shot outperformed a standard flu vaccine, supporting regulatory filings across major markets and potential approvals beginning in 2026. Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial
• Positive Sentiment: Multiple outlets report the mRNA‑1010 trial showed meaningful efficacy gains (reports cite roughly ~27% better performance vs standard shots in older adults), strengthening Moderna’s commercial vaccine pipeline and near‑term revenue prospects if regulators approve. Moderna mRNA flu vaccine beats standard shot, awaits FDA review
• Positive Sentiment: Analyst model update: Brookline Capital Markets raised FY2026 EPS expectations (less negative), narrowing downside to consensus estimates — a modest fundamental upgrade that supports valuation longer term.
• Positive Sentiment: Unusual options flow: traders bought ~102,888 call options (≈55% above typical daily call volume), indicating short‑term bullish/speculative positioning that can amplify intraday moves.
• Neutral Sentiment: Hantavirus reports tied to a cruise‑ship outbreak triggered an initial spike in interest for companies linked to infectious‑disease work; that news appears to have driven a rapid, sentiment‑driven rally rather than reflecting confirmed product activity. Moderna stock jumps 10% amid hantavirus outbreak concerns
• Neutral Sentiment: Coverage questioning whether Moderna began hantavirus mRNA work earlier (timeline/intent unclear) creates uncertainty but no confirmed program disclosures; this keeps any outbreak‑related upside speculative. Did Moderna Start Developing Hantavirus mRNA Vaccine in 2024? What We Know
• Negative Sentiment: After the intraday surge, the stock gave back much of its gains as traders digested the NEJM publication and event‑driven headlines — suggesting profit‑taking and that the hantavirus‑driven move was transient rather than a shift in fundamentals. Moderna Stock Gives Back Early Gains: What's Happening?

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Piper Sandler lifted their price target on Moderna from $63.00 to $69.00 and gave the stock an "overweight" rating in a report on Monday, February 23rd. Jefferies Financial Group set a $37.00 price target on Moderna and gave the stock a "hold" rating in a report on Tuesday, March 3rd. Morgan Stanley set a $33.00 price target on Moderna in a report on Friday, May 1st. Wall Street Zen upgraded Moderna from a "sell" rating to a "hold" rating in a report on Saturday, January 17th. Finally, Citigroup restated a "neutral" rating on shares of Moderna in a report on Monday, February 16th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Moderna currently has an average rating of "Reduce" and an average target price of $35.73.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.